Literature DB >> 27330149

Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.

Maurizio Infante1, Emanuela Morenghi2, Edoardo Bottoni3, Paolo Zucali4, Daoud Rahal5, Andrea Morlacchi3, Anna Maria Ascolese6, Fiorenza De Rose6, Pierina Navarria6, Alessandro Crepaldi3, Alberto Testori3, Emanuele Voulaz3, Valentina Errico3, Matteo Perrino4, Marta Scorsetti6, Arturo Chiti7, Armando Santoro4, Marco Alloisio3.   

Abstract

OBJECTIVES: We examined a series of malignant pleural mesothelioma (MPM) patients who underwent radical surgery to explore relationships among comorbidity, postoperative morbidity and survival.
METHODS: A retrospective analysis was carried out of all MPM patients operated on in a single centre from 2000 to 2015. The Charlson Comorbidity Index (CCI) was used to classify patients according to their underlying condition. Postoperative complications were scored according to WHO-derived criteria. Survival comparisons were performed by Cox analysis.
RESULTS: Ninety-one patients underwent extrapleural pneumonectomy (EPP), 47 underwent pleurectomy decortication (PD) and 25 underwent palliative pleurectomy. The mean CCI of PD patients was significantly higher compared with that of EPP patients (P= 0.044). The frequency of grade 3+ complications was similar between EPP and PD (27 vs 26%). However, EPP patients had a 6-fold higher frequency of pleural sepsis (24 vs 4%, P= 0.002) occurring up to 695 days postoperatively. Median overall survival was 19 months (95% CI 13-25) after EPP, 30 months (95% CI 20-35) after PD and 13 months (95% CI 5-32) after palliative pleurectomy. At multivariate analysis, CCI (P< 0.001), histology (P= 0.014) and pleural sepsis (P= 0.001), but not complete resection, were significantly associated with survival. There was a trend in favour of PD over palliative resection after adjusting for histology and CCI.
CONCLUSIONS: The CCI is an independent predictor of survival in MPM patients undergoing radical surgery. Owing to its significant frequency and adverse impact, pleural sepsis may contribute to a reduced life expectancy after EPP. Surgical treatment of MPM remains debatable.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Comorbidity; Extrapleural pneumonectomy; Malignant pleural mesothelioma; Palliative pleurectomy; Pleurectomy decortication

Mesh:

Year:  2016        PMID: 27330149     DOI: 10.1093/ejcts/ezw215

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

Review 1.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Extrapleural pneumonectomy: still indicated?

Authors:  Andreas Domen; Lawek Berzenji; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2018-10

3.  Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Ryotaro Kamohara; Go Hatachi; Takeshi Nagayasu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-01-23       Impact factor: 1.520

Review 4.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

7.  Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.

Authors:  Bub-Se Na; Ji Seong Kim; Kwanyong Hyun; In Kyu Park; Chang Hyun Kang; Young Tae Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2018-02-05

Review 8.  Multimodality treatment of malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul Van Schil
Journal:  F1000Res       Date:  2018-10-22

9.  The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Mesothelioma With Bone Metastasis.

Authors:  Runzhi Huang; Jiawen Wu; Zixuan Zheng; Guanghua Wang; Dianwen Song; Penghui Yan; Huabin Yin; Peng Hu; Xiaolong Zhu; Haiyun Wang; Qi Lv; Tong Meng; Zongqiang Huang; Jie Zhang
Journal:  Front Bioeng Biotechnol       Date:  2019-10-18

10.  Does size matter? -a population-based analysis of malignant pleural mesothelioma.

Authors:  Jiaxi He; Songhui Xu; Hui Pan; Shuben Li; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.